Related Experiment Video
Updated: Dec 12, 2025
06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.6K
Advance in circular RNA modulation effects of heart failure
Li Jiang1, Xiaoyan Wang2, Xiaopeng Zhan1
1Department of Cardiovascular Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Gene: X
|August 15, 2020
Summary
Circular RNAs (circRNAs) are stable noncoding RNA molecules. They play key roles in heart failure development and may offer novel therapeutic targets for treatment.
Area of Science:
- Molecular Biology
- Genetics
- Cardiovascular Research
Background:
- Circular RNAs (circRNAs) are endogenous noncoding RNA molecules with a stable, closed-loop structure.
- Unlike linear RNAs, circRNAs lack 5' cap and 3' poly(A) tails, rendering them resistant to exonuclease degradation.
- They are prevalent across eukaryotes, formed through exon or intron cyclization.
Purpose of the Study:
- To investigate the role of circRNAs in the pathogenesis of heart failure.
- To explore the potential of circRNAs as therapeutic targets for heart failure treatment.
Main Methods:
- Literature review and analysis of existing research on circRNAs and heart failure.
- Identification of key molecular mechanisms involving circRNAs in cardiac pathophysiology.
Main Results:
- CircRNAs are implicated in critical processes underlying heart failure, including cardiomyocyte hypertrophy, fibrosis, autophagy, and apoptosis.
- Their stability and regulatory functions highlight their significance in cardiac remodeling.
Conclusions:
- CircRNAs play a crucial role in the development and progression of heart failure.
- Emerging evidence suggests circRNAs represent promising novel therapeutic targets for heart failure intervention.
More Related Videos
05:15Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
1.9K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.8K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
759
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
759
01:29Heart Failure II: Pathophysiology
549
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
549
01:30Heart Failure V: Medical Management
130
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
130
01:30Cardiomyopathy II: Dilated Cardiomyopathy
288
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
288
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
312
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
312
01:17Pathophysiology of Heart Failure
2.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K